ORBIMED ADVISORS LLC 13D and 13G filings for X4 Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 7:36 pm Purchase |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ORBIMED ADVISORS LLC | 11,494,437 6.700% |
1,165,788 (+11.29%) |
Filing |
| 2023-02-14 5:24 pm Purchase |
2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ORBIMED ADVISORS LLC | 10,328,649 8.200% |
8,492,300 (+462.46%) |
Filing |
| 2022-02-11 5:08 pm Purchase |
2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ORBIMED ADVISORS LLC | 1,836,349 6.400% |
356 (+0.02%) |
Filing |
| 2021-03-25 4:15 pm Purchase |
2021-03-23 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ORBIMED ADVISORS LLC | 1,835,993 7.600% |
587,000 (+47.00%) |
Filing |